A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT study) - Manuel Perez-Garcia, Jose; Cortes Salgado, Alfonso; Lopez Miranda, Elena; Anton, Antonio; Sanchez Rovira, Pedro; Castelo Fernandez, Beatriz; Lopez Gonzalez, Ana; Garau, Isabel; Martinez, Alejandro; Corbellas Aparicio, Miguel; Del Barco, Sonia; Sampayo, Miguel; et al. (CANCER RESEARCH, 2020)